Trial Profile
A Phase 3, Open-Label, Safety Study of Lofexidine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Lofexidine (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Registrational
- Acronyms NU LEAF
- Sponsors US WorldMeds
- 06 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2015 New trial record